SUMMARYThis systematic review aimed at estimating chronic hepatitis B (HBV) and C virus (HCV)
prevalence in the European Union (EU) and Economic Area (EEA) countries in the general
population, blood donors and pregnant women. We searched PubMed©,
Embase© and Cochrane Library databases for reports on HBV and HCV prevalence in
the general population and pregnant women in EU/EEA countries published between 2005 and
2015. Council of Europe data were used for HBV and HCV blood donor prevalence. HBV general
population estimates were available for 13 countries, ranging from 0·1% to 4·4%. HCV
general population estimates were available for 13 countries, ranging from 0·1% to 5·9%.
Based on general population and blood donor estimates, the overall HBV prevalence in the
EU/EEA is estimated to be 0·9% (95% CI 0·7–1·2), corresponding to almost 4·7 million
HBsAg-positive cases; and the overall HCV prevalence to be 1·1% (95% CI 0·9–1·4),
equalling 5·6 million anti-HCV-positive cases. We found wide variation in HCV and HBV
prevalence across EU/EEA countries for which estimates were available, as well as
variability between groups often considered a proxy for the general population. Prevalence
estimates are essential to inform policymaking and public health practice. Comparing to
other regions globally, HBV and HCV prevalence in the EU/EEA is low.